Amendment: SEC Form SC 13G/A filed by Arvinas Inc.
$ARVN
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2026 | $15.00 | Neutral → Buy | Citigroup |
| 10/15/2025 | $6.00 | Neutral → Sell | Goldman |
| 9/24/2025 | $10.00 | Buy → Neutral | BofA Securities |
| 9/17/2025 | $16.00 | Overweight | Barclays |
| 6/2/2025 | $9.00 | Outperform → Market Perform | Leerink Partners |
| 5/5/2025 | $11.00 | Buy → Hold | Truist |
| 5/2/2025 | $10.00 | Buy → Hold | Jefferies |
| 5/2/2025 | Buy → Hold | TD Cowen |
4 - ARVINAS, INC. (0001655759) (Issuer)
4 - ARVINAS, INC. (0001655759) (Issuer)
4 - ARVINAS, INC. (0001655759) (Issuer)
4 - ARVINAS, INC. (0001655759) (Issuer)
– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – – ARV-102 (LRRK2) Phase 1 clinical data in patients with Parkinson's disease accepted for oral presentation at AP/PD Conference in March 2026 – – Clinical data from ARV-806 (KRAS G12D) and ARV-393 (BCL6) on track for presentations in 2026 – – Phase 1 trial in healthy volunteers initiated with polyQ-AR degrader ARV-027; first immuno-oncology PROTAC HPK1 degrader, ARV-6723, on track to initiate Phase 1 trial in mid-2026 – – Randy Teel, Ph.D., appointed President, Chief Executive Officer, and
NEW HAVEN, Conn, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Tuesday, March 3. Management will participate in a fireside chat, available here, at 1:10 p.m. ET.Leerink Global Healthcare Conference on Monday, March 9. Management will participate in a fireside chat, available here, at 4:20 p.m. ET.Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10. Management will participate in a fireside chat, available here, at
NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year 2025 financial results and provide a corporate update during a live webcast on Tuesday, February 24, 2026 at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About Arvinas Arvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company ded
Citigroup upgraded Arvinas from Neutral to Buy and set a new price target of $15.00
Goldman downgraded Arvinas from Neutral to Sell and set a new price target of $6.00
BofA Securities downgraded Arvinas from Buy to Neutral and set a new price target of $10.00
S-8 - ARVINAS, INC. (0001655759) (Filer)
10-K - ARVINAS, INC. (0001655759) (Filer)
8-K - ARVINAS, INC. (0001655759) (Filer)
Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham
– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of Directors – – Arvinas Board of Directors to Lead Search for CEO Replacement – NEW HAVEN, Conn., July 09, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., Chairperson, Chief Executive Officer (CEO) and President at Arvinas, has informed the Board of Directors of his plans to retire from his role as President and CEO following a search for, an
– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting– – Completion of enrollment in VERITAC-2 expected in 4Q24 and topline data readout now expected 4Q24/1Q25 – – Received $150 million upon close of ARV-766 license agreement and sale of preclinical AR-V7 program to Novartis; potential for up to an additional $1.01 billion based on achievement of development, regulatory and commercial milestones and future royalties – – Strengthened executive team with the appointm
SC 13G/A - ARVINAS, INC. (0001655759) (Subject)
SC 13G/A - ARVINAS, INC. (0001655759) (Subject)
SC 13G/A - ARVINAS, INC. (0001655759) (Subject)
– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – – ARV-102 (LRRK2) Phase 1 clinical data in patients with Parkinson's disease accepted for oral presentation at AP/PD Conference in March 2026 – – Clinical data from ARV-806 (KRAS G12D) and ARV-393 (BCL6) on track for presentations in 2026 – – Phase 1 trial in healthy volunteers initiated with polyQ-AR degrader ARV-027; first immuno-oncology PROTAC HPK1 degrader, ARV-6723, on track to initiate Phase 1 trial in mid-2026 – – Randy Teel, Ph.D., appointed President, Chief Executive Officer, and
NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year 2025 financial results and provide a corporate update during a live webcast on Tuesday, February 24, 2026 at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About Arvinas Arvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company ded
– Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson's disease – – Presented preclinical data from ARV-806 demonstrating robust and differentiated activity in models of KRAS G12D-mutated cancer – – Presented preclinical data from ARV-027 demonstrating robust degradation of polyQ-AR in muscle, supporting further evaluation as a potentially disease-modifying therapy in SBMA – – Announced agreement with Pfizer to jointly select a third party for the commercialization and potential further development of vepdegestrant – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., Nov. 05, 2025 (GLOBE NEWSWIRE)